The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
BUSINESS
Jury Finds Enhertu Infringes Seagen Patent, Awards US$41.8 Million in Damages
A US federal jury has found that Daiichi Sankyo’s cancer drug Enhertu (trastuzumab deruxtecan) infringes a patent owned by Seagen, awarding the US firm US$41.8 million in damages, the Japanese company said. Daiichi Sankyo is poised to challenge the verdict.…
To read the full story
Related Article
- Daiichi Sankyo’s ADC Arbitration Win Finalized with No Appeal
July 1, 2024
- US Patent Office Nixes Seagen Patent in ADC Row: Daiichi Sankyo
January 18, 2024
- Daiichi Sankyo Wins ADC Patent Row against Seagen, Appeals Unfavorable Ruling in Enhertu Suit
November 21, 2023
- Daiichi Sankyo Ordered to Pay 8% Royalty to Seagen in ADC Patent Row
October 19, 2023
- US Patent Office Restarts PGR for Seagen Patent: Daiichi Sankyo
February 20, 2023
- US Arbitrator Rejects Seagen’s Claims against Daiichi Sankyo in ADC Feud
August 16, 2022
- Texas Court Favors Seagen in Enhertu Patent Row, Daiichi Sankyo Poised to Challenge Ruling
July 21, 2022
BUSINESS
- 25 Japan Drug Makers’ Total Operating Profit Tops 2 Trillion Yen for 1st Time: Tally
May 20, 2025
- Chugai’s PNH Drug PiaSky Approved in Taiwan
May 20, 2025
- Japan’s Big 4 Wholesalers Log Operating Margin of 1.24%, All Break 1% Mark: Tally
May 19, 2025
- Sawai Wins Lawsuit over CML Use in Sprycel Generic
May 19, 2025
- Boehringer Ingelheim, Kanagawa Join Hands in Disease Prevention
May 19, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…